دورية أكاديمية

[Evaluation of two COVID-19 antigenic diagnostic tests: BIOSYNEX ® COVID-19 Ag BSS and BIOSYNEX ® COVID-19 Ag + BSS compared to AmpliQuick ® SARS-CoV-2 PCR ].

التفاصيل البيبلوغرافية
العنوان: [Evaluation of two COVID-19 antigenic diagnostic tests: BIOSYNEX ® COVID-19 Ag BSS and BIOSYNEX ® COVID-19 Ag + BSS compared to AmpliQuick ® SARS-CoV-2 PCR ].
عنوان ترانسليتريتد: Evaluation de deux tests de diagnostic antigénique du COVID-19: BIOSYNEX ® COVID-19 Ag BSS et BIOSYNEX ® COVID-19 Ag+ BSS comparés à la PCR AmpliQuick ® SARS-CoV-2 .
المؤلفون: Ngaba GP; Faculté de Médecine et des Sciences Pharmaceutiques, Université de Douala, Douala, Cameroun.; Hôpital Gynéco-Obstétrique et Pédiatrique de Douala, Douala, Cameroun., Kalla GCM; Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun., Assob JCN; Faculté de Médecine et des Sciences Pharmaceutiques, Université de Douala, Douala, Cameroun., Njouendou AJ; Faculté des Sciences de la Santé, Université de Buea, Buea, Cameroun., Jembe CN; Ministère de la Santé publique, District de santé de Deïdo, Douala, Cameroun., Mboudou ET; Hôpital Gynéco-Obstétrique et Pédiatrique de Douala, Douala, Cameroun.; Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun., Mbopi-Keou FX; Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun.; Institut pour le Développement de l'Afrique (The-IDA), Yaoundé, Cameroun.
المصدر: The Pan African medical journal [Pan Afr Med J] 2021 Aug 06; Vol. 39, pp. 228. Date of Electronic Publication: 2021 Aug 06 (Print Publication: 2021).
نوع المنشور: Comparative Study; Journal Article
اللغة: French
بيانات الدورية: Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Kampala, Uganda : African Field Epidemiology Network
مواضيع طبية MeSH: Antigens, Viral/*analysis , COVID-19/*diagnosis , COVID-19 Testing/*methods , Polymerase Chain Reaction/*methods, Adolescent ; Adult ; Aged ; Cameroon ; Child ; Child, Preschool ; Cross-Sectional Studies ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Predictive Value of Tests ; SARS-CoV-2 ; Sensitivity and Specificity ; Young Adult
مستخلص: Introduction: the COVID-19 pandemic causes biological diagnostic problems that remain relevant in low-income countries in general and in Cameroon in particular. Rapids tests that reliably detect SARS-CoV-2 virus antigen present themselves as an important alternative in several contexts. The objective of our study was to evaluate the diagnostic performance of two rapid diagnostic tests BIOSYNEX ® COVID-19 Ag BSS and BIOSYNEX ® COVID-19 Ag + BSS, compared to each other and to the AmpliQuick ® SARS-CoV-2 PCR test.
Methods: a cross-sectional and comparative study was carried out from April 27 to May 29, 2021 in the city of Douala in Cameroon. The samples consisted of nasopharyngeal swabs received at the molecular biology laboratory of the Douala Gyneco-obstetric and pediatric hospital, whatever their origin. The socio-demographic parameters (age, profession, football players, travelers, others), marital status, nationality), comorbidity and known status of COVID-19, were recorded on the collection sites. The main collection sites were the Deïdo Health District and the Douala Gyneco-Obstetric and Pediatric Hospital. We performed the diagnosis of COVID-19 using the rapid diagnostic test (RDT) BIOSYNEX ® COVID-19 Ag BSS and RDT BIOSYNEX ® COVID-19 Ag + BSS compared to each other and to the AmpliQuick ® SARS-CoV-2 polymerase chain reaction (PCR) test on each sample. Statistical analysis of the data was performed using Microsoft Excel and SPSS version 17 software. To determine the sensitivity of the two RDTs, the Bayesian latent class model was performed on the median with a 95% confidence interval with p<0.05 as the significant level. An ethical clearance was sought and obtained from the University of Douala Institutional Ethics Committee.
Results: a total of 1813 participants were included in our study, with a predominance of men (1226, 68.68 %) and the most represented age group was that of 31 to 40 years (568, 31.33 %). Most of the participants were married (888, 53.46%) and only a few had a known COVID-19 status (75, 5.47%). The two rapid tests on our study population show much closed COVID-19 prevalence values, respectively 2.03 for BIOSYNEX ® COVID-19 Ag BSS and 2.17 for BIOSYNEX ® COVID-19 Ag + BSS. RDT BIOSYNEX ® COVID-19 Ag + BSS showed higher sensitivity 94.1% vs. 87.5% for RDT BIOSYNEX ® COVID-19 Ag BSS with almost identical specificity 98.9% for RDT BIOSYNEX ® COVID-19 Ag + BSS vs. 98.7% for RDT BIOSYNEX ® COVID-19 Ag BSS compared to AmpliQuick ® SARS-CoV-2. BIOSYNEX ® COVID-19 Ag + BSS RDT showed a negative predictive value of 99.9% compared to BIOSYNEX ® COVID-19 Ag BSS RDT. There is a 99.9% agreement between the RDT BIOSYNEX ® COVID-19 Ag BSS and the RDT BIOSYNEX ® COVID-19 Ag + BSS. Conclusion : the RDT BIOSYNEX ® COVID-19 Ag + BSS and RDT BIOSYNEX ® COVID-19 Ag BSS can be used for the diagnosis of SARS-CoV-2 and can have an important contribution in the context of mass screenings and screening in remote areas.
Competing Interests: Les auteurs ne déclarent aucun conflit d´intérêts.
(Copyright: Guy Pascal Ngaba et al.)
References: Clin Infect Dis. 2020 Dec 26;:. (PMID: 33367619)
Lancet Infect Dis. 2020 Dec;20(12):1367-1368. (PMID: 32618280)
Front Pediatr. 2021 Jul 15;9:647274. (PMID: 34336732)
J Clin Microbiol. 2021 Mar 19;59(4):. (PMID: 33509809)
Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
PLoS One. 2013 Nov 12;8(11):e79489. (PMID: 24265775)
فهرسة مساهمة: Keywords: AmpliQuick® SARS-CoV-2; BIOSYNEX® COVID-19 Ag BSS; BIOSYNEX® COVID-19 Ag+ BSS; Cameroun; Douala; Evaluation
المشرفين على المادة: 0 (Antigens, Viral)
تواريخ الأحداث: Date Created: 20211011 Date Completed: 20211018 Latest Revision: 20220427
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8486925
DOI: 10.11604/pamj.2021.39.228.30752
PMID: 34630840
قاعدة البيانات: MEDLINE
الوصف
تدمد:1937-8688
DOI:10.11604/pamj.2021.39.228.30752